Drug Profile
DM 199
Alternative Names: DM-199; DM-99; Recombinant human tissue kallikrein-1 - DiaMedica Therapeutics; rhKLK-1 - DiaMedicaLatest Information Update: 23 Jun 2023
Price :
$50
*
At a glance
- Originator DiaMedica
- Developer DiaMedica; DiaMedica Therapeutics
- Class Antidementias; Antihyperglycaemics; Antirheumatics; Insulin sensitisers; Nootropics; Recombinant proteins; Urologics; Vascular disorder therapies
- Mechanism of Action Tissue kallikrein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Stroke
- Phase II Renal failure; Type 2 diabetes mellitus
- No development reported Diabetic nephropathies; Type 1 diabetes mellitus
- Discontinued Acute kidney injury; Alzheimer's disease; Lupus nephritis; Rheumatoid arthritis
Most Recent Events
- 21 Jun 2023 US FDA removes clinical hold on the phase II/III ReMEDy2 trial of DM 199 in Stroke
- 15 May 2023 DiaMedica Therapeutics plans to file a clinical hold response with the US FDA by the end of May 2023
- 15 May 2023 DiaMedica Therapeutics completes a phase-I clinical trials in Stroke in Australia (IV)